These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 11025787)

  • 1. Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack.
    Sarasin FP; Gaspoz JM; Bounameaux H
    Arch Intern Med; 2000 Oct; 160(18):2773-8. PubMed ID: 11025787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
    Jones L; Griffin S; Palmer S; Main C; Orton V; Sculpher M; Sudlow C; Henderson R; Hawkins N; Riemsma R
    Health Technol Assess; 2004 Oct; 8(38):iii-iv, 1-196. PubMed ID: 15461876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
    Greenhalgh J; Bagust A; Boland A; Martin Saborido C; Oyee J; Blundell M; Dundar Y; Dickson R; Proudlove C; Fisher M
    Health Technol Assess; 2011 Sep; 15(31):1-178. PubMed ID: 21888837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of clopidogrel-aspirin versus aspirin alone for acute transient ischemic attack and minor stroke.
    Pan Y; Wang A; Liu G; Zhao X; Meng X; Zhao K; Liu L; Wang C; Johnston SC; Wang Y; Wang Y;
    J Am Heart Assoc; 2014 Jun; 3(3):e000912. PubMed ID: 24904018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.
    Coleman CI; Straznitskas AD; Sobieraj DM; Kluger J; Anglade MW
    Am J Cardiol; 2012 Apr; 109(7):1020-5. PubMed ID: 22221944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
    Kirshner HS
    Int J Clin Pract; 2007 Oct; 61(10):1739-48. PubMed ID: 17877660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis.
    Shah H; Gondek K
    Clin Ther; 2000 Mar; 22(3):362-70; discussion 360-1. PubMed ID: 10963290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of antiplatelet agents in secondary stroke prevention: the limits of certainty.
    Matchar DB; Samsa GP; Liu S
    Value Health; 2005; 8(5):572-80. PubMed ID: 16176495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.
    Niu PP; Guo ZN; Jin H; Xing YQ; Yang Y
    BMJ Open; 2016 Mar; 6(3):e009013. PubMed ID: 26988347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone.
    Schleinitz MD; Heidenreich PA
    Ann Intern Med; 2005 Feb; 142(4):251-9. PubMed ID: 15710958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.
    Bath PM; Woodhouse LJ; Appleton JP; Beridze M; Christensen H; Dineen RA; Duley L; England TJ; Flaherty K; Havard D; Heptinstall S; James M; Krishnan K; Markus HS; Montgomery AA; Pocock SJ; Randall M; Ranta A; Robinson TG; Scutt P; Venables GS; Sprigg N;
    Lancet; 2018 Mar; 391(10123):850-859. PubMed ID: 29274727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
    Kourlaba G; Fragoulakis V; Maniadakis N
    Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole.
    Chambers M; Hutton J; Gladman J
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):577-93. PubMed ID: 10662482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
    Logman JF; Heeg BM; Herlitz J; van Hout BA
    Appl Health Econ Health Policy; 2010; 8(4):251-65. PubMed ID: 20578780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet Therapy After Noncardioembolic Stroke.
    Greving JP; Diener HC; Reitsma JB; Bath PM; Csiba L; Hacke W; Kappelle LJ; Koudstaal PJ; Leys D; Mas JL; Sacco RL; Algra A
    Stroke; 2019 Jul; 50(7):1812-1818. PubMed ID: 31177983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials.
    Geeganage CM; Diener HC; Algra A; Chen C; Topol EJ; Dengler R; Markus HS; Bath MW; Bath PM;
    Stroke; 2012 Apr; 43(4):1058-66. PubMed ID: 22282894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis.
    Schleinitz MD; Weiss JP; Owens DK
    Am J Med; 2004 Jun; 116(12):797-806. PubMed ID: 15178495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke.
    Hilkens NA; Algra A; Diener HC; Bath PM; Csiba L; Hacke W; Kappelle LJ; Koudstaal PJ; Leys D; Mas JL; Sacco RL; Greving JP
    Stroke; 2021 Oct; 52(10):3258-3265. PubMed ID: 34304604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial.
    Diener HC; Bogousslavsky J; Brass LM; Cimminiello C; Csiba L; Kaste M; Leys D; Matias-Guiu J; Rupprecht HJ;
    Lancet; 2004 Jul 24-30; 364(9431):331-7. PubMed ID: 15276392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adding aspirin to clopidogrel after TIA and ischemic stroke: benefits do not match risks.
    Hankey GJ; Eikelboom JW
    Neurology; 2005 Apr; 64(7):1117-21. PubMed ID: 15824331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.